Wall Street Eyes Hair Loss Treatments as Next Big Investment
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Wall Street Eyes Hair Loss Treatments as Next Big Investment
- The global prescription hair loss and hair removal drugs market is projected to reach an estimated value of $34.59 billion in 2026, with a compound annual growth rate of 7.3% from 2026 to 2033.
- Veradermics Inc. (trading as MANE), a clinical-stage biopharmaceutical company, has seen its shares rise significantly since its initial public offering in February 2026, following positive clinical trial results for its oral hair loss treatment, VDPHL01.
Full Summary — powered by AI
The pharmaceutical industry is increasingly focusing on developing new treatments for hair loss, attracting significant investor interest. This surge in attention is partly due to the substantial market for hair loss solutions, which currently has limited approved drug options. Pattern hair loss affects an estimated 50 million men and 30 million women in the United States alone. Historically, only a few drugs, such as topical minoxidil (Rogaine) and oral finasteride (Propecia), have been available, with no new drug approvals since the late 1990s.
One company at the forefront of this new wave is Veradermics Inc., which went public in February 2026. Their experimental oral treatment, VDPHL01, an extended-release formulation of minoxidil, met its primary goal in a Phase 3 trial in April 2026, demonstrating significant hair regrowth in men with male pattern baldness. The company also reported positive Phase 2 clinical trial results for VDPHL01 in women with female pattern hair loss in July 2026. These promising results have led to a substantial increase in Veradermics’ stock value, with shares rising nearly 500% since its IPO. If approved, VDPHL01 could be the first new oral pill specifically for baldness in approximately 30 years.
Other companies are also exploring novel approaches. Pelage Pharmaceuticals is developing a topical gel, PP405, designed to activate dormant hair follicle stem cells. Absci, utilizing an AI-driven discovery platform, is working on an antibody to stimulate hair growth. Cosmo is also developing clascoterone, a topical treatment for male-pattern baldness, with plans for a US application in early 2027. The global hair loss medications market is projected to reach USD 3.14 billion in 2026 and grow to USD 4.45 billion by 2031, with a compound annual growth rate of 7.19%. North America is a dominant region in this market, holding an estimated 40.8% share in 2026, driven by high awareness and advanced healthcare infrastructure.